Randomized Controlled Trial on Cardiovascular Exercise in Uncontrolled Epilepsy: (Epilepsy)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03570489 |
Recruitment Status :
Terminated
(Could not recruit patients because of Covid 19 restrictions and because of lack of efficacy for primary endpoint)
First Posted : June 27, 2018
Last Update Posted : November 15, 2021
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | May 28, 2018 | ||||
First Posted Date ICMJE | June 27, 2018 | ||||
Last Update Posted Date | November 15, 2021 | ||||
Actual Study Start Date ICMJE | November 30, 2018 | ||||
Actual Primary Completion Date | October 6, 2021 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Proportion of patients with at least 50% seizure reduction [ Time Frame: Change from baseline at 6months ] Determined by seizure diary
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Randomized Controlled Trial on Cardiovascular Exercise in Uncontrolled Epilepsy: | ||||
Official Title ICMJE | Randomized Controlled Study of the Effect of Cardiovascular Exercise in Uncontrolled Epilepsy: Efficacy, Side Effects and Quality of Life | ||||
Brief Summary | This is an open-label randomized controlled tria testing if an improvement in cardiovascular fitness can improve quality of Life and reduce seizure frequency in patients with refractory epilepsy.. Before the intervention each subject will undergo an evaluation of baseline cardiovascular fitness. Patients will be randomized into two groups One group will listen to a relaxation tape 5 days per week for 6 months and the other group will receive a ergometric cycle and perform a predetermined level of exercise per day , 5 days per week for 6 months. Randomization will be conducted an external randomization center based on a sequence of random numbers. Changes in concomitant antiepileptic drugs (AED) treatment during the study will be minimized, and restricted to AED changes deemed to be necessary to address AED-related toxicity. Medical examination; body weight; fitness test, including ECG and BP measurements, seizure frequency; adverse effects (unstructured interview); details of concomitant concomitant treatment, mood assessment by using the Hospital Anxiety and Depression Scale-Anxiety (HADS); health related quality of life (RAND-36), E4-data downloading, will be done at baseline and after 6 months Primary endpoint: Proportion of patients with at least 50% seizure reduction Secondary endpoints: Median percent reduction in seizure frequency, HADS score, RAND-36 score, fitness score; adverse events, changes in concomitant AED treatment, E4 data . |
||||
Detailed Description | Objectives The primary objective of this study is to assess the effect of a 6-month course of standardized physical exercise, added on to pre-existing stable AED treatment, on seizure frequency in patients with epilepsy aged 16 to 65. Secondary objectives include the assessment of the effect of a 6-month course of standardized physical exercise, added on to pre-existing stable AED treatment, on (i) depressive and anxiety symptom scores; (2) health-related quality of life; (3) adverse events. Study design Open-label randomized controlled trial. Before the intervention each subject will undergo an evaluation of cardiovascular fitness using the cycle ergometric test and his/her work level ((Wmax/kg) transformed into a stanine (1-9) score. Patients will be randomized into two groups by applying a stratification procedure which will allow a similar proportion of patients with high fitness (stanine score 5 to 9) and low fitness (stanine score 1 to 4) in both groups. Randomization will be conducted by telephone through an external randomization center based on a sequence of random numbers. Of the two randomized groups, one (Intervention group) will receive a course of standardized physical exercise for at least 5 days per week while the other group (control group) will randomize to listening to a computerized disc (CD) on muscular relaxation.. Changes in concomitant AED treatment during the study will not be allowed unless for adverse events related to the AEDs. Study procedures Patients considered to be eligible for the study will undergo initially a 4-week prospective baseline to ascertain baseline seizure frequency. After confirming their eligibility based on seizure frequency recording, patients will be examined by a study physician and by a physical therapist who will conduct an ergonomic test with a stationary bicycle under ECG and blood pressure monitoring to determine the level of cardiovascular fitness required for stratification. Thereafter the patients will be randomized to the intervention and the control group. The intervention group will receive a course of standardized physical exercise designed to fulfill the Swedish recommendations (FYSS) on exercise for disease-prevention (150 min per week of average intensity); at least 5 days per week for 6 months using a bicycle ergometer for 30 minutes a day. An individually adjusted workload will be determined by the physical therapist to achieve moderate intensity workout based on maximal oxygen uptake (VO2)max and percentage of maximal heart rate. Patients in the other group (control group) will be randomized to listen to a CD on muscular relaxation every day for 20 minutes and continue with their usual lifestyle. At enrollment, subjects randomized to the intervention group will be provided with a bicycle ergometer. requirements) as well parameters related to seizure activity. The following evaluations will be conducted at the times indicated, which correspond to hospital visits: Time 0 (enrollment): Medical examination; body weight; fitness test (Åstrand submax test, which is a submaximal test of aerobic fitness.), including ECG and BP measurements, seizure frequency (last 4 weeks); adverse effects (unstructured interview); details of concomitant concomitant treatment, mood assessment by using the Hospital Anxiety and Depression Scale-Anxiety (HADS); health related quality of life (RAND-36). Month 1, 2, 3, 4 and 5: Seizure frequency (recorded daily on seizure calendars), adverse effects (unstructured interview); body weight; details of concomitant treatment, E4-data downloading, advice on exercise from physical therapist. Month 6: Medical examination; body weight; fitness test, including ECG and BP measurements, seizure frequency; adverse effects (unstructured interview); details of concomitant concomitant treatment, mood assessment by using the Hospital Anxiety and Depression Scale-Anxiety (HADS); health related quality of life (RAND-36), E4-data downloading, Any additional testing (e.g. EEG, laboratory tests) may be performed as considered clinically indicated by the treating physician. Sample size and statistical analysis Assuming that 40% of patients in the intervention group vs. 20% of patients in the control group have a 50% or greater reduction in seizure frequency compared with baseline, 79 patients per group provide 80% power to identify a difference between groups at a significance level of 0.05. To account for potential dropouts, a total of 100 patients per group will be randomized. The primary analysis will be intent-to-treat (ITT) using "The Last Observation Carried Forward " (LOCF) extrapolation when appropriate. Per-protocol analysis (PPT) will exclude patients discontinuing prematurely the study and patients with less than 75% compliance with exercise requirements. Ethical aspects The study protocol has been approved by the Ethics Committees of Gothenburg in behalf of the participating centers. Before the study, all patients will be informed about the objectives and implications of the study, and will be asked to sign an informed consent form. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Open label randomized parallel design Masking: None (Open Label)Primary Purpose: Treatment |
||||
Condition ICMJE | Refractory Epilepsy | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Terminated | ||||
Actual Enrollment ICMJE |
28 | ||||
Original Estimated Enrollment ICMJE |
100 | ||||
Actual Study Completion Date ICMJE | October 6, 2021 | ||||
Actual Primary Completion Date | October 6, 2021 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 16 Years to 65 Years (Child, Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Sweden | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03570489 | ||||
Other Study ID Numbers ICMJE | ALFGBG-818131 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Vastra Gotaland Region | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Vastra Gotaland Region | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | Vastra Gotaland Region | ||||
Verification Date | October 2019 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |